85 related articles for article (PubMed ID: 9045928)
1. Sensitivity of Epstein-Barr virus-induced B cell tumor to apoptosis mediated by anti-CD95/Apo-1/fas antibody.
Durandy A; Le Deist F; Emile JF; Debatin K; Fischer A
Eur J Immunol; 1997 Feb; 27(2):538-43. PubMed ID: 9045928
[TBL] [Abstract][Full Text] [Related]
2. Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells.
Daniel PT; Krammer PH
J Immunol; 1994 Jun; 152(12):5624-32. PubMed ID: 7515909
[TBL] [Abstract][Full Text] [Related]
3. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
4. Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells.
Bohlen H; Manzke O; Titzer S; Lorenzen J; Kube D; Engert A; Abken H; Wolf J; Diehl V; Tesch H
Cancer Res; 1997 May; 57(9):1704-9. PubMed ID: 9135012
[TBL] [Abstract][Full Text] [Related]
5. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma.
Tafuku S; Matsuda T; Kawakami H; Tomita M; Yagita H; Mori N
Eur J Haematol; 2006 Jan; 76(1):64-74. PubMed ID: 16343273
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of HHV-8/KSHV infected primary effusion lymphomas in NOD/SCID mice by azidothymidine and interferon-alpha.
Wu W; Rochford R; Toomey L; Harrington W; Feuer G
Leuk Res; 2005 May; 29(5):545-55. PubMed ID: 15755507
[TBL] [Abstract][Full Text] [Related]
7. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
8. Ligation of HLA class II molecules promotes sensitivity to CD95 (Fas antigen, APO-1)-mediated apoptosis.
Yoshino T; Cao L; Nishiuchi R; Matsuo Y; Yamadori I; Kondo E; Teramoto N; Hayashi K; Takahashi K; Kamikawaji N
Eur J Immunol; 1995 Aug; 25(8):2190-4. PubMed ID: 7545111
[TBL] [Abstract][Full Text] [Related]
9. A humanized anti-human Fas antibody, R-125224, induces apoptosis in type I activated lymphocytes but not in type II cells.
Nakayama J; Ogawa Y; Yoshigae Y; Onozawa Y; Yonemura A; Saito M; Ichikawa K; Yamoto T; Komai T; Tatsuta T; Ohtsuki M
Int Immunol; 2006 Jan; 18(1):113-24. PubMed ID: 16361317
[TBL] [Abstract][Full Text] [Related]
10. Imatinib mesylate reduces rituximab-induced tumor-growth inhibition in vivo on Epstein-Barr virus-associated human B-cell lymphoma.
Némati F; Mathiot C; Grandjean I; Lantz O; Bordier V; Dewulf S; Ekue R; Di Santo JP; Poupon MF; Decaudin D
Anticancer Drugs; 2007 Oct; 18(9):1029-37. PubMed ID: 17704653
[TBL] [Abstract][Full Text] [Related]
11. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines.
Weller M; Frei K; Groscurth P; Krammer PH; Yonekawa Y; Fontana A
J Clin Invest; 1994 Sep; 94(3):954-64. PubMed ID: 7521890
[TBL] [Abstract][Full Text] [Related]
12. Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice.
Guinness ME; Kenney JL; Reiss M; Lacy J
Cancer Res; 2000 Oct; 60(19):5354-8. PubMed ID: 11034070
[TBL] [Abstract][Full Text] [Related]
13. Antirheumatic effects of humanized anti-Fas monoclonal antibody in human rheumatoid arthritis/SCID mouse chimera.
Matsuno H; Yudoh K; Nakazawa F; Sawai T; Uzuki M; Nishioka K; Yonehara S; Nakayama J; Ohtsuki M; Kimura T
J Rheumatol; 2002 Aug; 29(8):1609-14. PubMed ID: 12180717
[TBL] [Abstract][Full Text] [Related]
14. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
[TBL] [Abstract][Full Text] [Related]
15. Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2.
Egle A; Villunger A; Kos M; Böck G; Gruber J; Auer B; Greil R
Eur J Immunol; 1996 Dec; 26(12):3119-26. PubMed ID: 8977313
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice.
de Kroon JF; de Paus RA; Kluin-Nelemans HC; Kluin PM; van Bergen CA; Munro AJ; Hale G; Willemze R; Falkenburg JH
Exp Hematol; 1996 Jul; 24(8):919-26. PubMed ID: 8690051
[TBL] [Abstract][Full Text] [Related]
17. Follicular dendritic cells protect malignant B cells from apoptosis induced by anti-Fas and antineoplastic agents.
Schwarz YX; Yang My; Qin D; Wu J; Jarvis WD; Grant S; Burton GF; Szakal AK; Tew JG
J Immunol; 1999 Dec; 163(12):6442-7. PubMed ID: 10586034
[TBL] [Abstract][Full Text] [Related]
18. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo.
Rensing-Ehl A; Frei K; Flury R; Matiba B; Mariani SM; Weller M; Aebischer P; Krammer PH; Fontana A
Eur J Immunol; 1995 Aug; 25(8):2253-8. PubMed ID: 7545115
[TBL] [Abstract][Full Text] [Related]
19. Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis.
Uslu R; Borsellino N; Frost P; Gárban H; Ng CP; Mizutani Y; Belldegrun A; Bonavida B
Clin Cancer Res; 1997 Jun; 3(6):963-72. PubMed ID: 9815772
[TBL] [Abstract][Full Text] [Related]
20. Ligation of CD40 potentiates Fas-mediated activation of the cysteine protease CPP32, cleavage of its death substrate PARP, and apoptosis in Ramos-Burkitt lymphoma B cells.
An S; Yap D; Knox KA
Cell Immunol; 1997 Nov; 181(2):139-52. PubMed ID: 9398401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
